Strongbridge Biopharma plc [NASDAQ: SBBP] jumped around 0.48 points on Tuesday, while shares priced at $4.05 at the close of the session, up 13.45%. The company report on August 4, 2020 that Strongbridge Biopharma plc Reports Second Quarter 2020 Financial Results and Provides Corporate Update.
~ Reports KEVEYIS® (dichlorphenamide) Second Quarter 2020 Revenue of $7.8 Million, a 28 Percent Increase Compared to $6.1 Million During Second Quarter of 2019 ~.
~ Company Expects to Report Top-Line Results from the Phase 3 LOGICS Study of RECORLEV™ (levoketoconazole) in Endogenous Cushing’s Syndrome in September 2020 ~.
Strongbridge Biopharma plc stock is now 93.78% up from its year-to-date (YTD) trading value. SBBP Stock saw the intraday high of $4.07 and lowest of $3.4997 per share. The company’s 52-week high price is 4.63, which means current price is +170.00% above from all time high which was touched on 06/19/20.
Compared to the average trading volume of 338.31K shares, SBBP reached a trading volume of 1429754 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Strongbridge Biopharma plc [SBBP]?
Craig Hallum have made an estimate for Strongbridge Biopharma plc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 03, 2020. The new note on the price target was released on September 25, 2019, representing the official price target for Strongbridge Biopharma plc stock. Previously, the target price had yet another raise to $8, while Jefferies analysts kept a Buy rating on SBBP stock.
The Average True Range (ATR) for Strongbridge Biopharma plc is set at 0.26, with the Price to Sales ratio for SBBP stock in the period of the last 12 months amounting to 9.56. The Price to Book ratio for the last quarter was 3.58, with the Price to Cash per share for the same quarter was set at 1.11.
How has SBBP stock performed recently?
Strongbridge Biopharma plc [SBBP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 14.41. With this latest performance, SBBP shares gained by 6.30% in over the last four-week period, additionally plugging by 21.62% over the last 6 months – not to mention a rise of 63.97% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SBBP stock in for the last two-week period is set at 61.19, with the RSI for the last a single of trading hit 67.03, and the three-weeks RSI is set at 58.76 for Strongbridge Biopharma plc [SBBP]. The present Moving Average for the last 50 days of trading for this stock 3.66, while it was recorded at 3.60 for the last single week of trading, and 2.66 for the last 200 days.
Strongbridge Biopharma plc [SBBP]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Strongbridge Biopharma plc [SBBP] shares currently have an operating margin of -292.02 and a Gross Margin at +58.84. Strongbridge Biopharma plc’s Net Margin is presently recorded at -228.14.
Return on Total Capital for SBBP is now -67.84, given the latest momentum, and Return on Invested Capital for the company is -53.11. Return on Equity for this stock declined to -53.42, with Return on Assets sitting at -34.35. When it comes to the capital structure of this company, Strongbridge Biopharma plc [SBBP] has a Total Debt to Total Equity ratio set at 2.01. Additionally, SBBP Total Debt to Total Capital is recorded at 1.97, with Total Debt to Total Assets ending up at 1.24. Long-Term Debt to Equity for the company is recorded at 1.50, with the Long-Term Debt to Total Capital now at 1.47.
Reflecting on the efficiency of the workforce at the company, Strongbridge Biopharma plc [SBBP] managed to generate an average of -$696,493 per employee. Receivables Turnover for the company is 11.07 with a Total Asset Turnover recorded at a value of 0.15.Strongbridge Biopharma plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.80 and a Current Ratio set at 2.90.
Earnings analysis for Strongbridge Biopharma plc [SBBP]
With the latest financial reports released by the company, Strongbridge Biopharma plc posted -0.25/share EPS, while the average EPS was predicted by analysts to be reported at -0.27/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 7.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SBBP. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Strongbridge Biopharma plc go to 20.00%.
Insider trade positions for Strongbridge Biopharma plc [SBBP]
There are presently around $105 million, or 66.00% of SBBP stock, in the hands of institutional investors. The top three institutional holders of SBBP stocks are: CAXTON CORP with ownership of 6,612,065, which is approximately 0% of the company’s market cap and around 1.50% of the total institutional ownership; NEA MANAGEMENT COMPANY, LLC, holding 4,141,308 shares of the stock with an approximate value of $16.77 million in SBBP stocks shares; and IKARIAN CAPITAL, LLC, currently with $13.74 million in SBBP stock with ownership of nearly New of the company’s market capitalization.
Positions in Strongbridge Biopharma plc stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 34 institutional holders increased their position in Strongbridge Biopharma plc [NASDAQ:SBBP] by around 6,311,200 shares. Additionally, 33 investors decreased positions by around 6,690,839 shares, while 8 investors held positions by with 12,942,353 shares. The mentioned changes placed institutional holdings at 25,944,392 shares, according to the latest SEC report filing. SBBP stock had 14 new institutional investments in for a total of 4,469,846 shares, while 16 institutional investors sold positions of 5,212,959 shares during the same period.